MARK WAYNIK: Open Payments
NPI 1588738256 · FAIRFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,940 in 365 payments from 20 companies in 2025. Trend: 2023 $7,207 · 2024 $7,564 · 2025 $7,940
Food & beverage: $7,940
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 32 | $1,037 |
| Otsuka America Pharmaceutical, Inc. | 44 | $950 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $810 |
| ABBVIE INC. | 36 | $773 |
| Corium, LLC | 30 | $608 |
| E.R. Squibb & Sons, L.L.C. | 42 | $596 |
| Axsome Therapeutics, Inc. | 13 | $406 |
| Alkermes, Inc. | 16 | $401 |
| Lundbeck LLC | 22 | $396 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $364 |
Products named: INGREZZA, REXULTI, CAPLYTA, VRAYLAR, Azstarys, COBENFY, Auvelity, ARISTADA.
Industry payments across CT — which companies pay providers there.
